Francesco Innocenti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francesco Innocenti has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Gediz Dogay Us
School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands
3 shared publications - Ger H. Koek
School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, 6211 LK Maastricht, The Netherlands
3 shared publications - Gerard J. P. van Breukelen
Department of Methodology and Statistics, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
3 shared publications - Math J. J. M. Candel
Department of Methodology and Statistics, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
3 shared publications - Zeynep Banu Gungor
Department of Medical Biochemistry, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
3 shared publications - Fleur Veldman
Department of Gastroenterology‐Hepatology, NUTRIM Research Institute of Nutrition and Translational Research in Metabolism Maastricht University Medical Center Maastricht the Netherlands
2 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (5) , 659-674
Prevalence and Burden of Fatigue Across Disorders of Gut–Brain Interaction: Results From the Rome Foundation Global Epidemiology Study
Background: Overlap among disorders of gut‐brain interaction (DGBI) is common, with many patients experiencing concomitant non‐gastrointestinal symptoms. Fatigue is frequently reported, yet population‐based prevalence estimates across DGBI are limited. Aims: To examine the prevalence and burden of fatigue among DGBI. Methods: Data were derived from the Rome Foundation Global Epidemiology Study's internet‐based survey, conducted in 26 countries using the Rome IV Adult Diagnostic Questionnaire. Fatigue was assessed with single items from the Patient‐Reported Outcomes Measurement Information System (PROMIS) Global‐10 and the Patient Health Questionnaire‐12 (PHQ‐12). Prevalence of fatigue was compared across three groups, including no DGBI, one DGBI and multiple DGBI, with potential associated factors examined using logistic regression. Results: Among 54,127 participants (49% female; mean age 44 years), 59.9% had no DGBI, 26.6% had one DGBI and 13.5% had multiple DGBI. Fatigue prevalence was higher with more DGBI overlap: PROMIS 7.7% (95% CI:7.46–8.04), 16.4% (95% CI: 15.79–17.00), 30.2% (95% CI: 29.16–31.26); PHQ‐12 12.6% (95% CI: 12.24–12.96), 25.8% (95% CI: 25.06–26.49), 42.0% (95% CI: 40.83–43.09) for no, one, and multiple DGBI. Fatigue was most common in reflux hypersensitivity (PROMIS 46%, PHQ‐12 58%) and irritable bowel syndrome (PROMIS 39%, PHQ‐12 53%). Among individuals with DGBI, fatigue was consistently associated across both definitions with female sex, age, BMI, sleep disturbance, higher anxiety and depression scores, greater somatic symptom burden, lower psychological well‐being, antidepressant use, and satiety, abdominal pain, and bloating. Conclusions: Fatigue is common and burdensome in DGBI, particularly with overlapping diagnoses. Given the cross‐sectional design, directionality between fatigue and DGBI symptom burden remains unclear. Future research should employ longitudinal fatigue assessments to inform targeted management.
- 28 May 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (5) , 659-674
Open AccessPrevalence and Burden of Fatigue Across Disorders of Gut–Brain Interaction: Results From the Rome Foundation Global Epidemiology Study
Background: Overlap among disorders of gut‐brain interaction (DGBI) is common, with many patients experiencing concomitant non‐gastrointestinal symptoms. Fatigue is frequently reported, yet population‐based prevalence estimates across DGBI are limited. Aims: To examine the prevalence and burden of fatigue among DGBI. Methods: Data were derived from the Rome Foundation Global Epidemiology Study's internet‐based survey, conducted in 26 countries using the Rome IV Adult Diagnostic Questionnaire. Fatigue was assessed with single items from the Patient‐Reported Outcomes Measurement Information System (PROMIS) Global‐10 and the Patient Health Questionnaire‐12 (PHQ‐12). Prevalence of fatigue was compared across three groups, including no DGBI, one DGBI and multiple DGBI, with potential associated factors examined using logistic regression. Results: Among 54,127 participants (49% female; mean age 44 years), 59.9% had no DGBI, 26.6% had one DGBI and 13.5% had multiple DGBI. Fatigue prevalence was higher with more DGBI overlap: PROMIS 7.7% (95% CI:7.46–8.04), 16.4% (95% CI: 15.79–17.00), 30.2% (95% CI: 29.16–31.26); PHQ‐12 12.6% (95% CI: 12.24–12.96), 25.8% (95% CI: 25.06–26.49), 42.0% (95% CI: 40.83–43.09) for no, one, and multiple DGBI. Fatigue was most common in reflux hypersensitivity (PROMIS 46%, PHQ‐12 58%) and irritable bowel syndrome (PROMIS 39%, PHQ‐12 53%). Among individuals with DGBI, fatigue was consistently associated across both definitions with female sex, age, BMI, sleep disturbance, higher anxiety and depression scores, greater somatic symptom burden, lower psychological well‐being, antidepressant use, and satiety, abdominal pain, and bloating. Conclusions: Fatigue is common and burdensome in DGBI, particularly with overlapping diagnoses. Given the cross‐sectional design, directionality between fatigue and DGBI symptom burden remains unclear. Future research should employ longitudinal fatigue assessments to inform targeted management.
- Open Access
- 12 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341214
Prevalence of MASLD and fibrosis in Turkey: Results from a multicenter study of at-risk populations
Background: Turkey represents a high-risk setting for metabolic dysfunction-associated steatotic liver disease (MASLD), with national obesity and diabetes rates of 32% and 15%, respectively. Yet, no prior studies have systematically assessed MASLD and fibrosis prevalence and the independent contribution of these metabolic risk factors in at-risk Turkish populations exhibiting cardiometabolic risks. Methods: 1,039 adults were enrolled in a multicenter cross-sectional study conducted between 2022 and 2024. All participants presented with at least one of the current MASLD diagnostic criteria. Standardized clinical assessments were performed. Individuals with excessive alcohol consumption (2 . Obesity and central obesity were seen in 48.5% and 75.1% of the subjects, respectively. MASLD, significant fibrosis (>F2) and advanced fibrosis (>F3) prevalence were 57.5% (95% CI: 54.4%–60.4%), 7.6% (95% CI: 6.1%–9.4%) and 2.6% (95% CI: 1.8%–3.8%) respectively. Multivariable logistic regression of MASLD revealed a significant association with female sex (OR=0. 548; 95% CI: 0.391, 0.770), obesity (OR=2.208; 95% CI: 1.535, 3.177), insulin resistance (OR=2.09; 95% CI: 1.528, 2.881), metabolic syndrome (OR=2.436; 95% CI: 1.614, 3.679) and central obesity (OR=2.816; 95% CI: 1.725, 4.595). Multivariable logistic regression of fibrosis demonstrated a significant association with high income (OR=0.256; 95% CI: 0.069, 0.948), obesity (OR=4.845; 95% CI: 2.540, 9.242), diabetes, (OR=2.172; 95% CI: 1.306, 3.610), insulin resistance OR=4.205; 95% CI: 2.144, 8.246) and metabolic syndrome (OR=2.053; 95% CI: 1.042, 4.045). Conclusion: MASLD is prevalent in more than half of the at-risk population studied. Male sex, obesity, metabolic syndrome, insulin resistance and central obesity are significant risk factors associated with it. Despite the high MASLD prevalence, significant fibrosis is less prevalent and is associated with obesity, metabolic syndrome, insulin resistance and diabetes. Further research is warranted in this population. Study Registration: ClinicalTrials.gov, ID: NCT05194553 .
- 12 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341214
Open AccessPrevalence of MASLD and fibrosis in Turkey: Results from a multicenter study of at-risk populations
Background: Turkey represents a high-risk setting for metabolic dysfunction-associated steatotic liver disease (MASLD), with national obesity and diabetes rates of 32% and 15%, respectively. Yet, no prior studies have systematically assessed MASLD and fibrosis prevalence and the independent contribution of these metabolic risk factors in at-risk Turkish populations exhibiting cardiometabolic risks. Methods: 1,039 adults were enrolled in a multicenter cross-sectional study conducted between 2022 and 2024. All participants presented with at least one of the current MASLD diagnostic criteria. Standardized clinical assessments were performed. Individuals with excessive alcohol consumption (2 . Obesity and central obesity were seen in 48.5% and 75.1% of the subjects, respectively. MASLD, significant fibrosis (>F2) and advanced fibrosis (>F3) prevalence were 57.5% (95% CI: 54.4%–60.4%), 7.6% (95% CI: 6.1%–9.4%) and 2.6% (95% CI: 1.8%–3.8%) respectively. Multivariable logistic regression of MASLD revealed a significant association with female sex (OR=0. 548; 95% CI: 0.391, 0.770), obesity (OR=2.208; 95% CI: 1.535, 3.177), insulin resistance (OR=2.09; 95% CI: 1.528, 2.881), metabolic syndrome (OR=2.436; 95% CI: 1.614, 3.679) and central obesity (OR=2.816; 95% CI: 1.725, 4.595). Multivariable logistic regression of fibrosis demonstrated a significant association with high income (OR=0.256; 95% CI: 0.069, 0.948), obesity (OR=4.845; 95% CI: 2.540, 9.242), diabetes, (OR=2.172; 95% CI: 1.306, 3.610), insulin resistance OR=4.205; 95% CI: 2.144, 8.246) and metabolic syndrome (OR=2.053; 95% CI: 1.042, 4.045). Conclusion: MASLD is prevalent in more than half of the at-risk population studied. Male sex, obesity, metabolic syndrome, insulin resistance and central obesity are significant risk factors associated with it. Despite the high MASLD prevalence, significant fibrosis is less prevalent and is associated with obesity, metabolic syndrome, insulin resistance and diabetes. Further research is warranted in this population. Study Registration: ClinicalTrials.gov, ID: NCT05194553 .
- Open Access
Vitamin D Sufficiency Revisited: Evidence of a Dose–Response Effect for MASLD in Adults at Risk
Background and Aims: Vitamin D plays a pivotal role in liver health, influencing multiple steps in the development of steatosis, fibrosis, and extrahepatic complications in metabolic dysfunction-associated steatotic liver disease (MASLD). However, serum vitamin D concentrations that confer optimal hepatic protection in MASLD remain unclear. We therefore aimed to investigate the association between vitamin D status and MASLD and to explore whether higher vitamin D concentrations confer incremental protection beyond current sufficiency cut-offs. Method: We conducted a multicenter cross-sectional study of 1039 adults with at least one cardiometabolic risk factor for MASLD diagnosis, recruited between 2022 and 2024. Participants that reported excessive alcohol intake (>30 g/day for men, >20 g/day for women) and other etiologies of liver disease were excluded. Serum vitamin D levels were measured, with ≥20 ng/mL defined as sufficiency. MASLD (controlled attenuation parameter [CAP] ≥ 248 dB/m) and significant fibrosis (liver stiffness measurement [LSM] ≥ 8 kPa) were assessed using vibration-controlled transient elastography. Missing vitamin D values were imputed with multiple imputation. Associations between vitamin D status, MASLD and fibrosis were examined using multivariable logistic regression models adjusted for potential confounders. Results: Participants had a mean age of 52.2 ± 13.0 years; 51.6% were male and mean BMI was 30.1 ± 5.8 kg/m2. Vitamin D sufficiency and obesity were present in 81.2% (95% CI: 78.4–84.9) and 54.7% (95% CI: 51.3–58.0), respectively. Vitamin D sufficiency was associated with lower odds of MASLD (crude OR = 0.47, 95% CI: 0.33–0.67) and significant fibrosis (crude OR = 0.46, 95% CI: 0.28–0.76). After adjusting for potential confounders, the association between Vitamin D sufficiency and MASLD remained clinically relevant but did not reach statistical significance (adjusted OR = 0.60, 95% CI: 0.36–1.03, p = 0.06). In contrast, the association between Vitamin D sufficiency and significant fibrosis was both clinically relevant and statistically significant (adjusted OR = 0.48, 95% CI: 0.246–0.916, p = 0.03). When Vitamin D was categorized into quartiles, participants in the highest quartile (≥44 ng/dL) had 61% lower odds of MASLD in the adjusted model (adjusted OR = 0.39, 95% CI: 0.21–0.71) compared with participants in the lowest quartile (≤22 ng/mL). No significant dose-dependent associations were observed for fibrosis. Conclusions: Vitamin D levels showed a dose-dependent decrease in the odds of MASLD among at-risk adults. While the protective effect on fibrosis was not dose-dependent, these findings collectively suggest vitamin D as a potentially modifiable factor in MASLD prevention and management.
Open AccessVitamin D Sufficiency Revisited: Evidence of a Dose–Response Effect for MASLD in Adults at Risk
Background and Aims: Vitamin D plays a pivotal role in liver health, influencing multiple steps in the development of steatosis, fibrosis, and extrahepatic complications in metabolic dysfunction-associated steatotic liver disease (MASLD). However, serum vitamin D concentrations that confer optimal hepatic protection in MASLD remain unclear. We therefore aimed to investigate the association between vitamin D status and MASLD and to explore whether higher vitamin D concentrations confer incremental protection beyond current sufficiency cut-offs. Method: We conducted a multicenter cross-sectional study of 1039 adults with at least one cardiometabolic risk factor for MASLD diagnosis, recruited between 2022 and 2024. Participants that reported excessive alcohol intake (>30 g/day for men, >20 g/day for women) and other etiologies of liver disease were excluded. Serum vitamin D levels were measured, with ≥20 ng/mL defined as sufficiency. MASLD (controlled attenuation parameter [CAP] ≥ 248 dB/m) and significant fibrosis (liver stiffness measurement [LSM] ≥ 8 kPa) were assessed using vibration-controlled transient elastography. Missing vitamin D values were imputed with multiple imputation. Associations between vitamin D status, MASLD and fibrosis were examined using multivariable logistic regression models adjusted for potential confounders. Results: Participants had a mean age of 52.2 ± 13.0 years; 51.6% were male and mean BMI was 30.1 ± 5.8 kg/m2. Vitamin D sufficiency and obesity were present in 81.2% (95% CI: 78.4–84.9) and 54.7% (95% CI: 51.3–58.0), respectively. Vitamin D sufficiency was associated with lower odds of MASLD (crude OR = 0.47, 95% CI: 0.33–0.67) and significant fibrosis (crude OR = 0.46, 95% CI: 0.28–0.76). After adjusting for potential confounders, the association between Vitamin D sufficiency and MASLD remained clinically relevant but did not reach statistical significance (adjusted OR = 0.60, 95% CI: 0.36–1.03, p = 0.06). In contrast, the association between Vitamin D sufficiency and significant fibrosis was both clinically relevant and statistically significant (adjusted OR = 0.48, 95% CI: 0.246–0.916, p = 0.03). When Vitamin D was categorized into quartiles, participants in the highest quartile (≥44 ng/dL) had 61% lower odds of MASLD in the adjusted model (adjusted OR = 0.39, 95% CI: 0.21–0.71) compared with participants in the lowest quartile (≤22 ng/mL). No significant dose-dependent associations were observed for fibrosis. Conclusions: Vitamin D levels showed a dose-dependent decrease in the odds of MASLD among at-risk adults. While the protective effect on fibrosis was not dose-dependent, these findings collectively suggest vitamin D as a potentially modifiable factor in MASLD prevention and management.
- Open Access
- 24 December 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102176
Is FIB-4 the right tool for screening for liver fibrosis?
- 24 December 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102176
Open AccessIs FIB-4 the right tool for screening for liver fibrosis?
- Open Access
- 24 November 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Mediterranean and low-fat diets are equally effective in MASLD resolution at 12 weeks regardless of PNPLA3 genotype: A randomized controlled trial
Background: Dietary interventions are key for managing metabolic dysfunction–associated steatotic liver disease (MASLD), yet optimal diets and the role of PNPLA3 in modulating response to diet remain unclear. We evaluated the efficacy of a Mediterranean diet (MD) versus a low-fat diet (LFD) on hepatic fat and fibrosis, assessing interactions with PNPLA3 genotype. Methods: Two hundred fifty adults with MASLD with BMI ≥25 kg/m 2 were randomized to a 12-week moderately hypocaloric MD or LFD intervention. Individuals with excess alcohol intake and other etiologies of steatosis were excluded. Subjects were genotyped for PNLPA3 single-nucleotide polymorphism. Anthropometric measures, blood tests, and liver assessments [controlled attenuation parameter (CAP) and liver stiffness measurement (LSM)] were conducted at baseline and follow-up. Essential food items were provided, and adherence was tracked using validated questionnaires. The primary outcome was CAP, analyzed using linear mixed models adjusted for age and metabolic syndrome. Results: Both diets significantly reduced CAP, LSM, and body weight at follow-up, with no significant differences between groups. The mean difference between MD and LFD was −0.13 dB/m for CAP ( p =0.976, 95% CI: −8.54, 8.28), −0.19 kPa for LSM ( p =0.355, 95% CI: −0.58, 0.21), and 3.01 kg for weight ( p =0.159, 95% CI: −7.21, 1.19). PNPLA3 genotype did not significantly interact with diet for CAP, LSM, or weight ( p =0.286, p =0.464, p =0.622, respectively). Conclusions: Weight reduction achieved by MD and LFD is similarly efficient in steatosis and fibrosis reduction, while PNPLA3 genotype does not affect the response to diet. Further studies investigating the impact of diet and nutrigenetics on liver-related outcomes are warranted.
- 24 November 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Open AccessMediterranean and low-fat diets are equally effective in MASLD resolution at 12 weeks regardless of PNPLA3 genotype: A randomized controlled trial
Background: Dietary interventions are key for managing metabolic dysfunction–associated steatotic liver disease (MASLD), yet optimal diets and the role of PNPLA3 in modulating response to diet remain unclear. We evaluated the efficacy of a Mediterranean diet (MD) versus a low-fat diet (LFD) on hepatic fat and fibrosis, assessing interactions with PNPLA3 genotype. Methods: Two hundred fifty adults with MASLD with BMI ≥25 kg/m 2 were randomized to a 12-week moderately hypocaloric MD or LFD intervention. Individuals with excess alcohol intake and other etiologies of steatosis were excluded. Subjects were genotyped for PNLPA3 single-nucleotide polymorphism. Anthropometric measures, blood tests, and liver assessments [controlled attenuation parameter (CAP) and liver stiffness measurement (LSM)] were conducted at baseline and follow-up. Essential food items were provided, and adherence was tracked using validated questionnaires. The primary outcome was CAP, analyzed using linear mixed models adjusted for age and metabolic syndrome. Results: Both diets significantly reduced CAP, LSM, and body weight at follow-up, with no significant differences between groups. The mean difference between MD and LFD was −0.13 dB/m for CAP ( p =0.976, 95% CI: −8.54, 8.28), −0.19 kPa for LSM ( p =0.355, 95% CI: −0.58, 0.21), and 3.01 kg for weight ( p =0.159, 95% CI: −7.21, 1.19). PNPLA3 genotype did not significantly interact with diet for CAP, LSM, or weight ( p =0.286, p =0.464, p =0.622, respectively). Conclusions: Weight reduction achieved by MD and LFD is similarly efficient in steatosis and fibrosis reduction, while PNPLA3 genotype does not affect the response to diet. Further studies investigating the impact of diet and nutrigenetics on liver-related outcomes are warranted.
- Open Access
- 19 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2821
Prevalence and Risk Factors of MASLD in Prediabetes and Type 2 Diabetes Mellitus in Belgium and The Netherlands
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely intertwined with glucose metabolism status (GMS). Bi-national comparative epidemiological data are lacking; therefore, this study aimed to provide new insights into MASLD and fibrosis prevalence and risk factors in Belgium, while comparing data from The Netherlands to uncover cross-country differences. Materials and Methods: A prospective cohort study (2019–2024) in Belgian primary and secondary care was compared with the Dutch Maastricht Study. Liver fat was measured using CAP (FibroScan®), and anthropometric, clinical, and biochemical data were collected. Associations with CAP were analysed using multivariable linear regression, including sex, age, BMI, MetS, high SBP, CVD history, and country. Results: A total of 2436 individuals (Belgium and The Netherlands) were screened, of which 1928 were eligible: MASLD with normal GMS (38.3%), prediabetes (19.2%), and type 2 diabetes mellitus (T2DM; 42.5%). Belgian participants with T2DM had higher BMI and prevalence of MASLD. CAP values were significantly associated with female sex (−7.5 dB/m, 95%CI (−11.834; −3.056), p < 0.001), BMI (5.184 dB/m, 95%CI (4.627; 5.741), p < 0.001), and MetS (13.7 dB/m, 95%CI (8.456; 18.994), p < 0.001). Country-specific interactions showed differing effects of high SBP and CVD on CAP between Belgium and The Netherlands, with only the inverse association of CVD history (−10.756, 95%CI (−17.485; −4.027), p = 0.002) with CAP in The Netherlands being significant. Conclusions: MASLD and fibrosis are common in people with prediabetes and T2DM, underscoring the need for early detection and management. Obesity and metabolic risk were key factors, while a history of CVD appeared protective in the Dutch cohort but not in the Belgian one.
- 19 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2821
Open AccessPrevalence and Risk Factors of MASLD in Prediabetes and Type 2 Diabetes Mellitus in Belgium and The Netherlands
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely intertwined with glucose metabolism status (GMS). Bi-national comparative epidemiological data are lacking; therefore, this study aimed to provide new insights into MASLD and fibrosis prevalence and risk factors in Belgium, while comparing data from The Netherlands to uncover cross-country differences. Materials and Methods: A prospective cohort study (2019–2024) in Belgian primary and secondary care was compared with the Dutch Maastricht Study. Liver fat was measured using CAP (FibroScan®), and anthropometric, clinical, and biochemical data were collected. Associations with CAP were analysed using multivariable linear regression, including sex, age, BMI, MetS, high SBP, CVD history, and country. Results: A total of 2436 individuals (Belgium and The Netherlands) were screened, of which 1928 were eligible: MASLD with normal GMS (38.3%), prediabetes (19.2%), and type 2 diabetes mellitus (T2DM; 42.5%). Belgian participants with T2DM had higher BMI and prevalence of MASLD. CAP values were significantly associated with female sex (−7.5 dB/m, 95%CI (−11.834; −3.056), p < 0.001), BMI (5.184 dB/m, 95%CI (4.627; 5.741), p < 0.001), and MetS (13.7 dB/m, 95%CI (8.456; 18.994), p < 0.001). Country-specific interactions showed differing effects of high SBP and CVD on CAP between Belgium and The Netherlands, with only the inverse association of CVD history (−10.756, 95%CI (−17.485; −4.027), p = 0.002) with CAP in The Netherlands being significant. Conclusions: MASLD and fibrosis are common in people with prediabetes and T2DM, underscoring the need for early detection and management. Obesity and metabolic risk were key factors, while a history of CVD appeared protective in the Dutch cohort but not in the Belgian one.
- Open Access
- 16 October 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (1) , e70181
Socio‐Economic Determinants and Regional Prevalence of Disorders of Gut‐Brain Interaction in the Netherlands: Results From the Rome Foundation Global Epidemiology Study
Background: Disorders of gut‐brain interaction (DGBI) impose significant burdens worldwide, yet reliable regional prevalence estimates are lacking, limiting insight into potential geographic variation. Socio‐economic status (SES) may contribute but remains underexplored. Methods: Data were obtained from the Dutch cohort of the Rome Foundation Global Epidemiology Study, including the Rome IV Adult Diagnostic Questionnaire, sociodemographic items, and SES indicators. The Netherlands was divided into three regions (Region 1: South; Region 2: West; Region 3: North‐East). Regional prevalence was calculated for any DGBI, groups, and subtypes. Associations with SES were examined using logistic regression. Key Results: 2008 participants (50% female; age: 48 years [IQR: 31]; BMI: 25.25 kg/m 2 [IQR: 5.98]) were included. Overall DGBI prevalence was 30.63% (95% CI: 28.65–32.68), with no significant regional differences (Region 1: 30.40%, 95% CI [26.61–34.47]; Region 2: 30.19%, 95% CI [27.19–33.36]; Region 3: 31.45%, 95% CI [27.96–35.16]; p = 1.000). No regional variation was found across DGBI groups or subtypes (all p > 0.05). Younger age (OR = 0.98, 95% CI [0.98–0.99]), female sex (OR = 2.10, 95% CI [1.70–2.59]), underweight (OR = 2.53, 95% CI [1.36–4.73]), and obesity (OR = 1.59, 95% CI [1.19–2.13]) were associated with higher odds of DGBI. In models adjusted for age, sex, and BMI, limited/no healthcare access (OR = 2.47, 95% CI [1.62–3.77], p < 0.0001) was associated with higher DGBI odds, whereas employment showed lower odds (OR = 0.65, 95% CI [0.52–0.81], p < 0.001). Other SES indicators were not associated. Conclusion and Inferences: DGBI affect nearly one‐third of adults in the Netherlands, with no regional variation in prevalence. Putative risk factors include limited/no healthcare access and unemployment, supporting consideration of socioeconomic determinants in DGBI care, although further research is warranted.
- 16 October 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (1) , e70181
Open AccessSocio‐Economic Determinants and Regional Prevalence of Disorders of Gut‐Brain Interaction in the Netherlands: Results From the Rome Foundation Global Epidemiology Study
Background: Disorders of gut‐brain interaction (DGBI) impose significant burdens worldwide, yet reliable regional prevalence estimates are lacking, limiting insight into potential geographic variation. Socio‐economic status (SES) may contribute but remains underexplored. Methods: Data were obtained from the Dutch cohort of the Rome Foundation Global Epidemiology Study, including the Rome IV Adult Diagnostic Questionnaire, sociodemographic items, and SES indicators. The Netherlands was divided into three regions (Region 1: South; Region 2: West; Region 3: North‐East). Regional prevalence was calculated for any DGBI, groups, and subtypes. Associations with SES were examined using logistic regression. Key Results: 2008 participants (50% female; age: 48 years [IQR: 31]; BMI: 25.25 kg/m 2 [IQR: 5.98]) were included. Overall DGBI prevalence was 30.63% (95% CI: 28.65–32.68), with no significant regional differences (Region 1: 30.40%, 95% CI [26.61–34.47]; Region 2: 30.19%, 95% CI [27.19–33.36]; Region 3: 31.45%, 95% CI [27.96–35.16]; p = 1.000). No regional variation was found across DGBI groups or subtypes (all p > 0.05). Younger age (OR = 0.98, 95% CI [0.98–0.99]), female sex (OR = 2.10, 95% CI [1.70–2.59]), underweight (OR = 2.53, 95% CI [1.36–4.73]), and obesity (OR = 1.59, 95% CI [1.19–2.13]) were associated with higher odds of DGBI. In models adjusted for age, sex, and BMI, limited/no healthcare access (OR = 2.47, 95% CI [1.62–3.77], p < 0.0001) was associated with higher DGBI odds, whereas employment showed lower odds (OR = 0.65, 95% CI [0.52–0.81], p < 0.001). Other SES indicators were not associated. Conclusion and Inferences: DGBI affect nearly one‐third of adults in the Netherlands, with no regional variation in prevalence. Putative risk factors include limited/no healthcare access and unemployment, supporting consideration of socioeconomic determinants in DGBI care, although further research is warranted.
- Open Access
- 22 November 2023
- Published by American Educational Research Association (AERA) in Journal of Educational and Behavioral Statistics
- Vol. 49 (5) , 817-847
Sample Size Calculation and Optimal Design for Multivariate Regression-Based Norming
Normative studies are needed to obtain norms for comparing individuals with the reference population on relevant clinical or educational measures. Norms can be obtained in an efficient way by regressing the test score on relevant predictors, such as age and sex. When several measures are normed with the same sample, a multivariate regression-based approach must be adopted for at least two reasons: (1) to take into account the correlations between the measures of the same subject, in order to test certain scientific hypotheses and to reduce misclassification of subjects in clinical practice, and (2) to reduce the number of significance tests involved in selecting predictors for the purpose of norming, thus preventing the inflation of the type I error rate. A new multivariate regression-based approach is proposed that combines all measures for an individual through the Mahalanobis distance, thus providing an indicator of the individual’s overall performance. Furthermore, optimal designs for the normative study are derived under five multivariate polynomial regression models, assuming multivariate normality and homoscedasticity of the residuals, and efficient robust designs are presented in case of uncertainty about the correct model for the analysis of the normative sample. Sample size calculation formulas are provided for the new Mahalanobis distance-based approach. The results are illustrated with data from the Maastricht Aging Study (MAAS).
- 22 November 2023
- Published by American Educational Research Association (AERA) in Journal of Educational and Behavioral Statistics
- Vol. 49 (5) , 817-847
Open AccessSample Size Calculation and Optimal Design for Multivariate Regression-Based Norming
Normative studies are needed to obtain norms for comparing individuals with the reference population on relevant clinical or educational measures. Norms can be obtained in an efficient way by regressing the test score on relevant predictors, such as age and sex. When several measures are normed with the same sample, a multivariate regression-based approach must be adopted for at least two reasons: (1) to take into account the correlations between the measures of the same subject, in order to test certain scientific hypotheses and to reduce misclassification of subjects in clinical practice, and (2) to reduce the number of significance tests involved in selecting predictors for the purpose of norming, thus preventing the inflation of the type I error rate. A new multivariate regression-based approach is proposed that combines all measures for an individual through the Mahalanobis distance, thus providing an indicator of the individual’s overall performance. Furthermore, optimal designs for the normative study are derived under five multivariate polynomial regression models, assuming multivariate normality and homoscedasticity of the residuals, and efficient robust designs are presented in case of uncertainty about the correct model for the analysis of the normative sample. Sample size calculation formulas are provided for the new Mahalanobis distance-based approach. The results are illustrated with data from the Maastricht Aging Study (MAAS).
- 1 February 2023
- Published by American Psychological Association (APA) in Psychological Methods
- Vol. 28 (1) , 89-106
Sample size calculation and optimal design for regression-based norming of tests and questionnaires.
To prevent mistakes in psychological assessment, the precision of test norms is important. This can be achieved by drawing a large normative sample and using regression-based norming. Based on that norming method, a procedure for sample size planning to make inference on Z-scores and percentile rank scores is proposed. Sampling variance formulas for these norm statistics are derived and used to obtain the optimal design, that is, the optimal predictor distribution, for the normative sample, thereby maximizing precision of estimation. This is done under five regression models with a quantitative and a categorical predictor, differing in whether they allow for interaction and nonlinearity. Efficient robust designs are given in case of uncertainty about the regression model. Furthermore, formulas are provided to compute the normative sample size such that individuals' positions relative to the derived norms can be assessed with prespecified power and precision. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- 1 February 2023
- Published by American Psychological Association (APA) in Psychological Methods
- Vol. 28 (1) , 89-106
Sample size calculation and optimal design for regression-based norming of tests and questionnaires.
To prevent mistakes in psychological assessment, the precision of test norms is important. This can be achieved by drawing a large normative sample and using regression-based norming. Based on that norming method, a procedure for sample size planning to make inference on Z-scores and percentile rank scores is proposed. Sampling variance formulas for these norm statistics are derived and used to obtain the optimal design, that is, the optimal predictor distribution, for the normative sample, thereby maximizing precision of estimation. This is done under five regression models with a quantitative and a categorical predictor, differing in whether they allow for interaction and nonlinearity. Efficient robust designs are given in case of uncertainty about the regression model. Furthermore, formulas are provided to compute the normative sample size such that individuals' positions relative to the derived norms can be assessed with prespecified power and precision. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- 30 April 2021
- Published by Maastricht University
Efficient designs for mean estimation in multilevel populations and test norming
- 30 April 2021
- Published by Maastricht University
Efficient designs for mean estimation in multilevel populations and test norming